Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Part of paid clinical trials in Santa Monica, California.
- Sponsor
- PharmaMar
- Study ID
- NCT02451007
- Phase
- PHASE2
- Status
- Completed
Conditions
- Solid Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- lurbinectedin (PM01183) — DRUG
Study Details
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.
Key Dates
- Start date
- Aug 12, 2015
- Status verified
- Nov 2019
- Primary completion
- Aug 19, 2016
- Completion
- Aug 19, 2016
Study Design
- Enrollment
- 39 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: A (lurbinectedin)lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
Primary Outcome Measure
Change in QTcF (QT Corrected According to Fridericia's Formula) [ Time Frame: Scheduled post-baseline ECG time points were taken 5-10 min before their time-matched PK samples: i.e., 5 min before EOI, 30 min, 1, 3, 24, 72 and 168 hours after EOI of Cycle 1, and 5 min before EOI, 30 min, 1, 3 and 168 hours after EOI of Cycle 2. ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | - |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | - |
| Dana Farber Cancer lnstitute | Boston | Massachusetts | 02215 | - |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| Cancer Therapy & Research Center | San Antonio | Texas | 78229 | - |
Find similar trials in Santa Monica, CA
Related Studies
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)PHASE3 · Recruiting · Merck Sharp & Dohme LLC · Tucson, Arizona
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyPHASE2 · Recruiting · Spectrum Pharmaceuticals, Inc · Valhalla, New York
- S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Shionogi · Los Angeles, California